Immunotherapy targeting B cells and long-lived plasma cells effectively eliminates pre-existing donor-specific allo-antibodies
Zhang Z, Markmann C, Yu M, Agarwal D, Rostami S, Wang W, Liu C, Zhao H, Ochoa T, Parvathaneni K, Xu X, Li E, Gonzalez V, Khadka R, Hoffmann J, Knox J, Scholler J, Marcellus B, Allman D, Fraietta J, Samelson-Jones B, Milone M, Monos D, Garfall A, Naji A, Bhoj V. Immunotherapy targeting B cells and long-lived plasma cells effectively eliminates pre-existing donor-specific allo-antibodies. Cell Reports Medicine 2023, 4: 101336. PMID: 38118406, PMCID: PMC10772570, DOI: 10.1016/j.xcrm.2023.101336.Peer-Reviewed Original ResearchConceptsChimeric antigen receptorLong-lived plasma cellsB-cell maturation antigenAllo-antibodiesMultiple myelomaB cellsChimeric antigen receptor-T therapyEfficacy of chimeric antigen receptorAllo-transplantationAnti-human leukocyte antigenTarget B cellsMemory B cellsCART-19T therapyMaturation antigenLeukocyte antigenAntigen receptorClinical efficacyMurine modelPlasma cellsClinical evaluationHyperacute rejectionDesensitization approachImmunotherapyTransplantation